A PHASE 2 OPEN-LABEL STUDY OF STA-9090 FOR PATIENTS WITH METASTATIC BREAST CANCER.

Trial Profile

A PHASE 2 OPEN-LABEL STUDY OF STA-9090 FOR PATIENTS WITH METASTATIC BREAST CANCER.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Ganetespib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Dec 2011 Results were presented at the 2011 San Antonio Breast Cancer Symposium, according to a Synta Pharmaceuticals media release. They were also reported in the media release.
    • 04 Nov 2011 Results will be presented at the 2011 San Antonio Breast Cancer Symposium (SABCS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top